BSE filing, NSE: ABCAPITAL. Summary written from the filing by ALFA Finder's alert engine.
Aditya Birla Capital Ltd: key numbers
- Share price
- ₹356.00
- Market cap
- ₹97,473 Cr
- Revenue (annual)
- ₹45,509 Cr
- Net profit (annual)
- ₹3,764 Cr
- P/E (TTM)
- 23.8×Sector 21.7×
- Promoter holding
- 68.82%+0.01% QoQ
- FII holding
- 8.26%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Aditya Birla Capital Ltd
All →Aditya Birla Capital Employee Stock Options
Aditya Birla Capital allotted 24,884 equity shares under its ESOP/RSU/PSU schemes on October 23, 2026. Paid-up capital increased to 27,38,00,66,370 shares of ₹10 each.
Aditya Birla Capital Debt & Borrowing
Aditya Birla Capital Limited fixed record dates for interest payments on various NCD series due in December 2026.
Aditya Birla Capital Board Meeting Date
Aditya Birla Capital Limited scheduled a board meeting for October 30, 2026, to consider and approve unaudited financial results for the half-year ended September 2026.
Aditya Birla Capital Debt & Borrowing: ₹118.7 Cr
Aditya Birla Capital paid Rs. 118.65 Crore interest on its NCD Series 'G1'. This filing fulfills the mandatory debt servicing disclosure.
- Value
- ₹118.7 Cr
Aditya Birla Capital Debt & Borrowing: ₹13.51 Cr
Aditya Birla Capital clarified the interest amount as ₹2.79 crore for its NCD series II, alongside confirming the ₹10.73 crore redemption payment.
- Value
- ₹13.51 Cr
Aditya Birla Capital Debt & Borrowing: ₹216 Cr
Aditya Birla Capital has fully redeemed its secured NCDs (Series I and Series II), involving a total payout of ₹216.04 Crore.
- Value
- ₹216.0 Cr
Other other announcement announcements
All →Aarti Pharmalabs Other Announcement
Aarti Pharmalabs has intimated under Regulation 46 that it revamped its website at the existing URL to improve design and accessibility. The notice has no financial or business substance.
Sagarsoft (India) Other Announcement
Sagarsoft (India) filed its Regulation 32 fund utilisation statement for its 2021 preferential issue. No deviation was reported and the full Rs.5.08 Crore was used.
Sadhana Nitro Chem Other Announcement
Sadhana Nitro Chem reported no deviation in use of its preferential issue proceeds for the quarter ended September 2026. The Audit Committee reviewed the statement.
Shriram Asset Management Company Other Announcement
Shriram AMC filed ICRA's quarterly monitoring agency report on preferential issue proceeds. Utilisation is in line with the offer objects, with no deviation reported.
Jhandewalas Foods Other Announcement
Jhandewalas Foods filed its quarterly shareholding pattern for the period ended September 30, 2026. The filing records holdings by category and contains no transaction or money event.
Avience Biomedicals Other Announcement
Avience Biomedicals confirmed corporate governance compliance is not applicable, as it is SME-listed on NSE Emerge. No quarterly governance report is required for September 2026.